Therapy Areas: Central Nervous System
Collegium to acquire AZSTARYS from Corium Therapeutics
20 March 2026 - Collegium Pharmaceutical Inc (Nasdaq:COLL) and Corium Therapeutics Holdings LLC announced on Thursday a definitive agreement for Collegium to acquire AZSTARYS for USD650m in cash with ...
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
18 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designati...
GenomOncology partners with WeTrials to support CNS cancer clinical trials
11 March 2026 - Precision medicine software company GenomOncology announced on Tuesday that it has partnered with WeTrials, an AI-powered patient engagement and trial enablement platform, to help cent...
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
2 March 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that its Phase III FENhance 1 study in relapsing multiple sclerosis (RMS)...
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
27 February 2026 - Gemma Biotherapeutics (GEMMABio), a US-based clinical-stage global genetic medicines company, announced on Thursday that it has dosed its first parent in the Phase 1/2 CHARISMA clin...
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
20 February 2026 - Biopharmaceutical company Lario Therapeutics announced on Thursday that it has received a total of USD2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's R...